Kornimate/medical-research-clean huggingface dataset:
laughter therapy and mindfulness practices

Conditions: Nurse's Role

Summary: nurses working by shifts under intense stress and pressure and using complicated technological products- undergo fatigue and attention deficit with the effect of the many negative factors caused by work setting. this threatens patient and staff safety as well as leads to communicational problems, work absenteeism, lowered motivation, inability to control stress and poor work performance and productivity among nurses as well. in this sense; laughter therapy and mindfulness practices may help nurses cope with these problems because some experimental studies proved that both methods showed many benefits in different samples. however; no studies in which these two methods were compared among nurses were encountered. therefore; the study -being in experimental design and randomized controlled trial- will be undertaken with a total of 111 nurses employed at a university hospital -37 nurses allocated to the experimental 1 group, 37 nurses to the experimental 2 group and 37 nurses to the control group-. first; computer-based sustained attention test, the stroop test çapa version, the chalder fatigue scale (cfq) and individual work performance questionnaire will be administered to the nurses of the experimental and control groups as a pre-test. then; nurses of the experimental 1 group will join sessions of laughter therapy (30-45 minutes twice a week for 8 weeks) and nurses of the experimental 2 group will join sessions of mindfulness practices (45-60 minutes twice a week for 8 weeks) for two months. one month later when the sessions are started, a mid test will be administered and soon after the sessions are completed a post test will be administered to the nurses via computer-based sustained attention test, the stroop test çapa version, the chalder fatigue scale (cfq) and individual work performance questionnaire. one month later after the post test; a follow-up will be performed using the same tools. as a result; the effects of both applications on fatigue, attention and performance will be investigated.


Eligibility criteria:
inclusion criteria: * at least 6 months experience * volunteering * alternative work schedule exclusion criteria: * not being a nurse, * pregnancy * diagnosis of colour blindness, cardiovascular, psychological diseases * meditating before

Keywords: mindfulness, attention, laughter therapy, job performance, fatigue
caudal block with tramadol and levobupivacaine or bupivacaine

Conditions: Pain, Postoperative

Summary: caudal block is the regional anesthetic technique that is used most frequently in pediatric surgery. opioid drugs have been added to local anesthetic solutions to prolong duration of analgesia but ideal combination were not found that has minimal adverse effect. the aim of this study was to compare the postoperative analgesic efficacy of equal concentrations of bupivacaine plus tramadol or levobupivacaine plus tramadol in pediatric patients undergoing minor urological surgery.

sixty-eight children aged 2 to 7 years who were undergoing inguinal herniorrhaphy or orchidopexy received bupivacaine 0.25% plus tramadol 2 mg/kg (bt group) or levobupivacaine 0.25% plus tramadol 2 mg/kg (lt group) by the caudal route after laryngeal mask anesthesia. the primary outcome of the study was to compare the duration and quality of postoperative analgesia. the postoperative pain relief was evaluated by the children and infants postoperative pain scale (chipps) at 2, 4, 6, 12, and 24 h postoperatively. in addition, the time of first analgesic requirement was noted.

Eligibility criteria:
inclusion criteria: * asa i, * 2 to 7 years old children * elective inguinal herniorrhaphy or orchidopexy operation exclusion criteria: * infection at the site of block, bleeding diathesis, pre-existing neurological or spinal disease, or abnormalities of the sacrum) or with a known allergy to local anesthetics were excluded.
a single high-dose oral supplement of vitamin d in young chinese

Conditions: Vitamin D Deficiency

Summary: evaluated the effect and safety of a single high dose of cholecalciferol in chinese young people.


Eligibility criteria:
inclusion criteria: * healthy, younger, chinese hans aged from 25-35 years, including 25 and 35 years; * haven't taken vitamin d supplement for the past 6 months; * with a normal bmi (18-25 kg/m2); * with baseline serum 25(oh)d \< 30 ng/ml; * be willing to follow the instruction and complete the study. exclusion criteria: * clinically diagnosed cardiovascular disease, gastrointestinal disease, endocrine, blood, liver, lung, kidney, nerve or mental illness; * self-reported current use of any dietary supplements containing vitamin d within the 6 months before enrollment; * severe anemia (hemoglobin concentration \< 70 g/l); * serum 25(oh)d ≥ 30 ng/ml at enrollment; * participating in other research studies within the 3 months before enrollment; * history of drug dependence or drug abuse; * history of heavy drinking (drinking 14 cups or more per week, equivalent to 360 ml beer or 150 ml white wine or 45 ml liquor per cup) and smokers (more than 10 cigarette per day); * clinical abnormal of blood biochemistry, hematology or urine laboratory values; * current pregnancy or lactation.
albuterol and dynamic hyperinflation in idiopathic pulmonary arterial hypertension

Conditions: Idiopathic Pulmonary Arterial Hypertension.

Summary: the purpose of this study is to determine if dynamic hyperinflation seen in patients with idiopathic pulmonary artery hypertension (ipah) improves with albuterol therapy.

only a few small studies have evaluated the relationship between ipah, expiratory flow limitation, and exercise dyspnea. while not all patients with ipah demonstrate airway involvement, those who demonstrate dynamic hyperinflation (dh), defined as a variable and temporary increase in end-expiratory lung volume, report increased dyspnea with exertion on maximal testing. there is a continued need for adjuvant therapy in ipah, and bronchodilators have the potential to ameliorate dyspnea during exercise, which could lead to improved quality of life in this disabling condition. this study will investigate the presence of airway involvement in this population as measured by dynamic hyperinflation, and if there is any improvement in function with the use of inhaled albuterol.

Eligibility criteria:
inclusion criteria: * 18 years of age or greater. * idiopathic pulmonary arterial hypertension, or familial pulmonary arterial hypertension. * forced expiratory flow 75% (fef75%) of ≤ 65% of predicted. exclusion criteria: * clinical instability or change in medication therapy in preceding 3 months. * allergy or intolerance to inhaled albuterol. * body mass index \> 30 * active tobacco use, or \> 10 pack-year smoking history. * lung disease other than pulmonary hypertension * forced expiratory volume in 1 second (fev1) ≤ 80% of predicted. * pregnancy * inability to perform pulmonary function testing. * inability to perform cardiopulmonary exercise testing. * supplemental oxygen requirement. * inability to read and understand english. * historical 6-minute walk distance \<150 meters
evaluation of the safety and effectiveness of aceclidine (lnz101) and aceclidine + brimonidine (lnz100) in the treatment of presbyopia

Conditions: Presbyopia; Refractive Errors; Eye Diseases

Summary: to evaluate the safety and effectiveness of aceclidine/brimonidine (lnz101) compared with aceclidine (lnz100) and vehicle in the treatment of presbyopia.


Eligibility criteria:
inclusion criteria: 1. be able and willing to provide written informed consent and sign health information portability and accountability act (hipaa) form prior to any study procedure being performed; 2. be able and willing to follow all instructions and attend study visits; 3. be 45-75 years of age of either sex and any race or ethnicity at visit 1; 4. have +1.00 to -4.00 diopter(d) of sphere (so that spherical equivalent (se) results in myopia no more severe than -4.00d mrse. see inclusion 5 below) in both eyes determined by manifest refraction documented at visit 1; 5. have ≤ 2.00d of cylinder (minus cylinder) in both eyes determined by manifest refraction documented at visit 1; 6. be presbyopic as determined at visit 1 exclusion criteria: 1. be a female of childbearing potential who is currently pregnant, nursing or planning a pregnancy; 2. have known contraindications or sensitivity to the use of any of the study medications(s) or their components; 3. have an active ocular infection at visit 1 (bacterial, viral or fungal), positive history of an ocular herpetic infection, preauricular lymphadenopathy, or ongoing, active ocular inflammation (e.g., moderate to severe blepharitis, allergic conjunctivitis, peripheral ulcerative keratitis, scleritis, uveitis) in either eye; 4. have moderate or severe dry eye defined as total corneal fluorescein staining at visit 1; 5. have clinically significant abnormal lens findings in either eye during dilated slit-lamp biomicroscopy and fundus exam documented within 3 months of visit 1

Keywords: pharmaceutical solutions miotics ophthalmic solutions near vision eye drops insight 2
a study evaluating the efficacy and safety of ckd-314 in hospitalized adult patients diagnosed with covid-19 pneumonia

Conditions: COVID-19

Summary: the primary objective of this study is to evaluate the efficacy of ckd-314 (nafabelltan) compared to standard of care (soc), with respect to clinical status assessed by a 7-point ordinal scale in hospitalized adult patients diagnosed with covid-19 pneumonia

open-label, multi-center, randomized controlled, phase 2 clinical trial to evaluate the efficacy and safety of ckd-314 in hospitalized adult patients diagnosed with covid-19

Eligibility criteria:
inclusion criteria: * men and women aged ≥18 years * hospitalized subjects who have confirmed covid-19 infection and have evidence of pneumonia: * covid-19 infection: sars-cov-2 positive confirmed by rt-pcr * pneumonia: a reliable diagnosis of new lung infiltration on a chest ct scan or chest radiograph * subjects within 72 hours after confirmed covid-19 pneumonia * subjects with a seven-category ordinal scale of clinical status of 4 (hospitalization, requiring supplemental oxygen) or 5 (hospitalization, requiring nasal high-flow oxygen therapy and/or noninvasive mechanical ventilation) * subjects (or legally authorized representative) should be able to understand and agree to comply with the clinical trial and to provide a written consent document prior to initiation of any study procedure exclusion criteria: * subject has a serious chronic disease * subject requiring invasive mechanical ventilation at the time of screening * subject with rapidly(within 3 days) deteriorating clinical condition according to the investigator's opinion * subject who have a record of hiv or aids * subject taking corticosteroids\[however, ① steroids being used for the treatment of corona 19 (eg, dexamethasone, etc.), ② topical steroids, ③ patients who are administering inhaled steroids are not eligible for exclusion\] * subject taking immunosuppressants/immunomodulators * subject with liver cirrhosis whose child-pugh score is b or c * subject with hyperkalemia (k\> 5.1mmol/l) * subject who have liver disease abnormalities with alt or ast \> 5 times uln * estimated glomerular filtration rate (egfr) \< 30 ml/min * qtc \>500ms * subject who have hypersensitivity to the investigational drug * pregnant or lactating females * subject who are not appropriate for the study, as the investigator's opinion

Keywords: covid-19
brief pain and smoking cessation intervention in adults with chronic pain

Conditions: Smoking Cessation

Summary: a brief smoking cessation intervention was developed to address smoking in the context of chronic pain to increase the intention to engage in smoking cessation treatment.

the primary aim of this randomized controlled trial was to investigate the effects of a brief pain and smoking (bps) cessation intervention on the willingness to consider quitting smoking in adults with chronic pain seeking treatment in a pain specialty outpatient clinic. the investigators hypothesized that participants randomized to the bps intervention, relative to a brief non-tailored control smoking (bcs) intervention, would be more likely to self-report willingness to consider quitting smoking. secondary aims included examining the effects of group allocation on the (1) interest in learning about smoking cessation programs; (2) willingness to consider scheduling a smoking cessation program; (3) scheduling a smoking cessation program; and (4) change scores of the thoughts about abstinence scale (taas).

Eligibility criteria:
inclusion criteria: * age ≥18 years * chronic pain of greater than 3 months duration * smoke at least 10 cigarettes daily exclusion criteria: * cancer-related pain * current participation in a smoking abstinence program * current self-guided attempt to reduce or abstain from smoking * use of other forms of tobacco including pipe, cigar or chew * history of schizophrenia or other chronic psychotic disorder * history of a dementing illness
role of greyscale and power doppler sonography in therapy monitoring in early rheumatoid arthritis (ra)

Conditions: Rheumatoid Arthritis

Summary: the purpose of this study is to evaluate the role of musculoskeletal ultrasound and power doppler in early therapy monitoring of rheumatoid arthritis patients.


Eligibility criteria:
inclusion criteria: * adults: age at disease onset \>18 years and \< 50 years * disease duration \< 3 month * fulfilling ara criteria for classification of ra * dmard naive exclusion criteria: * age at diagnosis \< 18 years * disease duration \> 3 month * previous use of dmards * previous use of biologics
long-term trial on growth hormone deficiency in adults (ghda)

Conditions: Growth Hormone Disorder; Adult Growth Hormone Deficiency

Summary: this trial is conducted in japan. to investigate the long-term efficacy as assessed by change in fat mass and safety after 48 weeks of treatment of growth hormone in adults with growth hormone deficiency, comparing two different treatment regiments.


Eligibility criteria:
inclusion criteria: * subjects who completed ghliquid-1518. * if the subject has a history of treatment for a tumor of pituitary or peripheral site, two years or more have to be passed since completion of surgery, radiotherapy or other treatment, and recurrence of the underlying disease to be excluded. * appropriate replacement therapy has been administered for more than 24 weeks for the treatment of other pituitary hormone deficiencies. exclusion criteria: * subject with a history of acromegaly. * subject with diabetes mellitus. * subject suffering from malignancy. * several medical conditions
an amniotic membrane injection comparing two doses (1 ml and 2ml injection) in the treatment of osteoarthritis of the knee

Conditions: Osteoarthritis, Knee

Summary: the purpose of this study is to determine the dose effect of a single injectable acellular amniotic membrane derived allograft injection for the treatment of knee osteoarthritis and to confirm whether the use of 2 ml of the same amniotic injection offers a statistically significant advantage over the 1 ml injection.

it is a prospective, double blinded, randomized controlled trial study. data will be prospectively collected of all injectable acellular amniotic membrane derived allograft knee performed at our institute (1 vs 2 ml). 60 subjects will be enrolled in this study. subjects will be randomized 1:1 in treatment arms. each of the patient will be treated with one time injection to the knee. methods for collecting data will be through validated patient-reported outcome tools (koos, vas and womac questionnaire) that the patient will complete pre-injection and at specified time intervals after injection: 90 days, 180 days and 365 days.

Eligibility criteria:
inclusion criteria: * age of 21 to 80 years * diagnosis of osteoarthritis (oa) defined as grade 1 to 3 on the kellgren lawrence grading scale exclusion criteria: * subject has a diagnosis of osteoarthritis (oa) defined as grade 4 on the kellgren lawrence grading scale * bmi greater than 40 kg/m2 * subject has active infection at the injection site * symptomatic oa of the contralateral knee or of either hip that is not responsive to acetaminophen (tylenol) and requires other therapy. * subject has rheumatoid arthritis, psoriatic arthritis or has been diagnosed with any other disorder that is the primary source of their knee pain, including but not limited to: osteonecrosis, radiculopathy, bursitis, tendinitis, tumor or cancer * subject has documented history of gout or pseudo-gout * subject has an autoimmune disease or known history of having acquired immunodeficiency syndromes (aids) or hiv * subject has received any of the following to the target knee: 1. intra-articular hyaluronic acid (ha) injection within 12 weeks prior to screening 2. intra-articular cortisone (steroid/corticosteroid) injection into the knee joint within 12 weeks of treatment 3. steroid or platelet rich plasma (prp) injection within 12 weeks prior to screening 4. has had or is planning to have major surgery or arthroscopy in the target knee within 26 weeks of treatment * history of partial or total knee arthroplasty * subject has used an investigational drug, device or biologic within 12 weeks prior to treatment * subject has a history of immunosuppressive or chemotherapy in the last 5 years * subject has had prior radiation at the site * subject is currently taking narcotic medication for any reason. * subject is pregnant or plans to become pregnant within 365 days of treatment * subject has any significant medical condition that, in the opinion of the investigator, would interfere with protocol evaluation and participation * subject is a worker's compensation patient * subject is a prisoner

Keywords: osteoarthritis knee amniotic membrane allograft
handheld ultrasound device to triage women with a positive clinical breast examination by trained non-radiologists

Conditions: Breast Cancer; Carcinoma in Situ

Summary: cross sectional study to evaluate estimate accuracy of portable ultrasound device in correctly differentiating the benign breast lesions from the malignant ones in the women referred with a positive clinical breast examination (cbe) screening test.

more than two million new cases of breast cancer occur each year worldwide. implementing mammography screening is complex and resource-intensive, making it impractical in resource-limited settings. clinical breast examination (cbe) has been recommended as an alternative screening option for low- and middle-income countries. several studies have shown a significant shift towards earlier stage tumours detected by cbe. however, the high false-positive rate and low positive predictive value of cbe expose women to unnecessary and costly further diagnostic procedures, as well as the negative psychological consequences. there is an urgent need for a more accurate, cost-effective and reliable triage technology that can be performed by any healthcare provider.

Eligibility criteria:
inclusion criteria: * clinical breast examination positive women with no debilitating illness. * symptomatic women found to be positive on clinical breast examination by nurses/midwives or medical officers. exclusion criteria: * women with confirmed diagnosis of breast cancer or those already treated for the disease.

Keywords: breast cancer screening low- and middle-income countries clinical breast examination portable ultrasound device triage
genetics and hiv-1 protease inhibitors

Conditions: HIV

Summary: this study evaluated the blood levels of atazanavir according to a genetic makeup for cyp3a5 (cytochrome p450 3a5, an enzyme that metabolizes atazanavir). the hypothesis was that people with a slow-metabolizing genotype would have higher blood levels of atazanavir compared to people with the normal metabolizing genotype.


Eligibility criteria:
inclusion criteria: * age 18 to 55 years * negative hiv screening antibody test * cyp3a5 expressor status, race, and sex fit an enrollment opening. exclusion criteria: * pregnant or breast-feeding * medical history of * hepatitis b or c, * autoimmune disease, * active malignancy, * kidney disease including nephrolithiasis * organ dysfunction manifested by * liver transaminases or * serum creatinine \>1.25 times the upper limit of normal, or * any comprehensive metabolic test (except asymptomatic unconjugated hyperbilirubinemia), blood count, or lipid value \> grade i according to division of aids (daids) adverse drug event grading system (appendix). * medical history of arrhythmias (including atrial fibrillation, atrioventricular block, and/or pacemaker) * any qt interval abnormalities or other congenital arrhythmia syndromes on ecg or * any ecg abnormality that in the opinion of the investigators would preclude entry into the study. * medical history of any serious heart condition including: * congestive heart failure, * myopathies, * coronary artery disease, or * unexplained syncope. * medical history of bleeding disorders (i.e., hemophilia) * hyperlipidemia * any prescription, herbal, recreational, or over-the-counter medication contraindicated with ritonavir or atazanavir including: * substrates/inhibitors/inducers of cyp3a/p-gp, * cardio-active medication, or * medications that alter the acid in the stomach. the study investigators will review each concurrent medication on a case-by-case basis. * inability to refrain from grapefruit or grapefruit juice during the study. * investigational drugs within the last 30 days. * active alcohol / recreational drug abuse, * inability to give informed consent. * a body mass index below 18.5 or above 34.

Keywords: pharmacokinetics clinical pharmacology pharmacogenomics hiv
ocular microvascular changes in patients with sepsis

Conditions: Sepsis; Retinal Microcirculation Disorder; Conjunctiva; Disorder

Summary: this study evaluates differences in the ocular microcirculation between septic patients and healthy subjects and the course of ocular microvasculature in survivors and non-survivors over a 24 hours period of time in septic patients

conjunctival imaging, using idf video microscope, and retinal imaging, using portable digital fundus camera, as well as systemic hemodynamic measurements, were performed in septic patients at three time points: at baseline, 6 hours and 24 hours. baseline conjunctival and retinal microcirculatory parameters were compared with healthy controls.

Eligibility criteria:
inclusion criteria: * adult patients with sepsis or septic shock within the first 24 hours after icu admission exclusion criteria: * psychiatric disorders, brain diseases, chronic alcoholism, autoimmune rheumatic diseases * ophthalmological diseases, such as glaucoma, age-related macular degeneration, diabetic retinopathy and cataract

Keywords: conjunctival microcirculation retinal vessels fundus imaging idf imaging sepsis